Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 40

Related Articles by Review for PubMed (Select 18184092)

1.

Measuring HIV-1-specific T cell immunity: how valid are current assays?

D'Souza MP, Altfeld M.

J Infect Dis. 2008 Feb 1;197(3):337-9. doi: 10.1086/525288. No abstract available.

2.

T cell immune responses to HIV-1.

Vasan S, Schlesinger SJ, Arrode G.

Front Biosci. 2007 Jan 1;12:2330-43. Review.

PMID:
17127243
3.

Cross-clade T cell recognition of HIV.1.

Gotch F.

Curr Opin Immunol. 1998 Aug;10(4):388-92. Review.

PMID:
9722913
4.

Polyfunctional analysis of human t cell responses: importance in vaccine immunogenicity and natural infection.

Makedonas G, Betts MR.

Springer Semin Immunopathol. 2006 Nov;28(3):209-19. Epub 2006 Aug 25. Review. No abstract available.

PMID:
16932955
5.

Aiming for successful vaccine-induced HIV-1-specific cytotoxic T lymphocytes.

Yang OO.

AIDS. 2008 Jan 30;22(3):325-31. doi: 10.1097/QAD.0b013e3282f29491. Review. No abstract available.

PMID:
18195558
6.

HIV type 1 vaccine-induced cytotoxic T cell responses in phase I clinical trials: detection, characterization, and quantitation.

McElrath MJ, Siliciano RF, Weinhold KJ.

AIDS Res Hum Retroviruses. 1997 Feb 10;13(3):211-6. Review. No abstract available.

PMID:
9115806
7.

HIV type 1 vaccine-induced cytotoxic T cell responses: potential role in vaccine efficacy.

Ada GL, McElrath MJ.

AIDS Res Hum Retroviruses. 1997 Feb 10;13(3):205-10. Review. No abstract available.

PMID:
9115805
8.

HIV evolution in response to HLA-restricted CTL selection pressures: a population-based perspective.

Carlson JM, Brumme ZL.

Microbes Infect. 2008 Apr;10(5):455-61. doi: 10.1016/j.micinf.2008.01.013. Epub 2008 Feb 1. Review.

PMID:
18407775
9.

HIV/AIDS vaccines: 2007.

Robinson HL.

Clin Pharmacol Ther. 2007 Dec;82(6):686-93. Epub 2007 Oct 31. Review.

PMID:
17971817
10.

HIV vaccines 1983-2003.

McMichael AJ, Hanke T.

Nat Med. 2003 Jul;9(7):874-80. Review.

PMID:
12835708
11.

T lymphocyte responses in HIV-1 infection: implications for vaccine development.

Brander C, Walker BD.

Curr Opin Immunol. 1999 Aug;11(4):451-9. Review.

PMID:
10448136
12.

Will we be able to 'spot' an effective HIV-1 vaccine?

Yang OO.

Trends Immunol. 2003 Feb;24(2):67-72. Review.

PMID:
12547502
13.

The HIV-1 vaccine race.

Ho DD, Huang Y.

Cell. 2002 Jul 26;110(2):135-8. Review.

14.

Cellular immune responses to HIV-1 in progressive and non-progressive infections.

Bollinger RC, Egan MA, Chun TW, Mathieson B, Siliciano RF.

AIDS. 1996;10 Suppl A:S85-96. Review. No abstract available.

PMID:
8883615
15.

Developing an HIV cytotoxic T-lymphocyte vaccine: issues of CD8 T-cell quantity, quality and location.

Masopust D.

J Intern Med. 2009 Jan;265(1):125-37. doi: 10.1111/j.1365-2796.2008.02054.x. Review.

PMID:
19093965
16.

Obstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine.

Haut LH, Ertl HC.

J Leukoc Biol. 2009 Oct;86(4):779-93. doi: 10.1189/jlb.0209094. Epub 2009 Jul 13. Review.

17.

Conference on advances in AIDS vaccine development--1993. Summary: cytotoxic T-cell Immunity Workshop.

Walker MC, Walker BD, Mestecky J, Mathieson BJ.

AIDS Res Hum Retroviruses. 1994;10 Suppl 2:S177-9. Review. No abstract available.

PMID:
7865295
18.

Proving HIV-1 immunity: new tools offer new opportunities.

Picker LJ.

J Clin Invest. 2000 May;105(10):1333-4. Review. No abstract available.

19.

Human immunodeficiency virus interactions with CD8+ T lymphocytes.

Saksena NK, Wu JQ, Potter SJ, Wilkinson J, Wang B.

Curr HIV Res. 2008 Jan;6(1):1-9. Review.

PMID:
18288969
20.

Vaccines and immunology: elucidating immunity to HIV-1 and current prospects for AIDS vaccine development.

Heeney JL, Hahn BH.

AIDS. 2000;14 Suppl 3:S125-7. Review. No abstract available.

PMID:
11086855
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk